Table 61Characteristics of exenatide observational studies in adults with type 2 diabetes

Author, Year
Country
Sample size (N)
Follow-up (weeks)
Age (years) (SD)a
% Malea
% Whitea
% Hispanica
Diabetes duration (years)a
Baseline
HbA1c (%)a
Weight (kg)a
BMI (kg/m2)a
InterventionCombination therapyPrimary trial citations
Blonde, 2006
US
974
(551-ITT)
82
55(10)
61
74
12
7(6)
8.4(1.0)
98(20)
34(6)
10 mcg BIDMET +/− SUBuse, 2004
DeFronzo, 2005
Kendall, 2005
Buse, 2007
US
974
(521-ITT)
104
55(10)
59
74
12
8(6)
8.4(1.1)
99(20)
34(6)
10 mcg BIDNRBuse, 2004
DeFronzo, 2005
Kendall, 2005
King, 2006
US
200
12
NRNRNRNone or various (TZD, SU, MET, insulin)NA
Nelson, 2007
US
127
30
52(11)
44
76
6
3.9(4.5)
7.5(0.7)
100(19)
35(6)
10 mcg BIDMET or diet/exercise (“Study B”)NA
Ratner, 2006
US
150
(92 completers)
82
54(10)
69
86
1
5(5)
8.1(1.0)
102(21)
34(6)
10 mcg BIDMETDeFronzo, 2005
Riddle, 2006
US
518
(222 completers)
82
57(10) 61
75
12
8(6)
8.4(1.0)
99(21)
34(6)
10 mcg BIDSUBuse, 2004
Kendall, 2005
Fabunmi, 2009
US
6300
52
53–56
46–59
NR
NR
NR
7.7–9.5
NR
NR
Exenatide any doseMET, SU, TZD, or combinationNA

Abbreviations: BID, twice daily; ITT, intention-to-treat population; MET, metformin; NR, not reported; SU, sulfonylurea; TZD, thiazolidinedione.

a

Data presented are mean (standard deviation).

Data presented are mean (standard deviation).

From: Results

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.